Institute for Infection and Immunity, St. George's University of London, SW18 0RE, London, UK.
Biopharming Research Unit, Molecular & Cell Biology Department, University of Cape Town, Cape Town, South Africa.
Curr Opin Biotechnol. 2020 Feb;61:53-59. doi: 10.1016/j.copbio.2019.10.005. Epub 2019 Nov 18.
Interest in applications and benefits that Molecular Pharming might offer to Low and Middle Income Countries has always been a potent driver for the research discipline, and a major reason why many scientists entered the field. Although enthusiasm remains high, the reality is that such a game-changing innovation would always take longer than traditional uptake of new technology in developed countries, and be complicated by external factors beyond technical feasibility. Excitingly, signs of increasing interest by LMICS in Molecular Pharming are now emerging. Here, three case studies from Thailand, South Africa and Brazil are used to identify some of the key issues when a new investment into Molecular Pharming manufacturing capacity is under consideration. At present, academic research is not necessarily addressing these issues. Only by understanding the concerns, can members of the academic community contribute to helping the development of Molecular Pharming for LMICs by focusing their research efforts appropriately.
对低、中收入国家可能从分子农业中获得的应用和益处的兴趣一直是该研究领域的强大动力，也是许多科学家进入该领域的主要原因。尽管热情依然高涨，但现实情况是，这种改变游戏规则的创新总是需要比发达国家采用新技术的时间长得多，并且会受到技术可行性以外的外部因素的影响。令人兴奋的是，低、中收入国家对分子农业日益增长的兴趣迹象正在出现。在这里，我们从泰国、南非和巴西选取了三个案例研究，以确定在考虑新投资分子农业生产能力时需要考虑的一些关键问题。目前，学术研究并不一定能解决这些问题。只有了解这些问题，学术界的成员才能通过有针对性地调整研究工作，为分子农业在低、中收入国家的发展做出贡献。
